Symposium
Thu. May 24, 2018 3:20 PM - 5:20 PM Room 8 (Royton Sapporo / Empress Hall （2F）)
Chair: Hiroyuki Murai(Department of Neurology, International University of Health and Welfare, Japan), Masakatsu Motomura(Medical Engineering Course, Nagasaki Institute of Applied Science, Japan)
The development of myasthenia gravis (MG) treatment is remarkable these days. The Japanese clinical guidelines for MG was published in 2014, setting the treatment goal as minimal manifestations with oral prednisolone of 5 mg/day or below, and encouraged that treatment strategies should strive to attain this level as rapidly as possible. Early fast-acting treatment is a powerful strategy for this purpose. Eculizumab is a monoclonal antibody that binds to complement protein C5 and may be beneficial to treat refractory MG. Numbers of treatment trials are in progress internationally. Here, we will discuss with an international panel the way to pursue the best treatment strategy of MG.
○Hiroyuki Murai (Department of Neurology, International University of Health and Welfare, Japan)
Schedule
Like
)
○Ted M. Burns (University of Virginia, USA)
Schedule
Like
)
○James F. Howard Jr (The University of North Carolina at Chapel Hill, USA)
Schedule
Like
)
○Kimiaki Utsugisawa (Department of Neurology, Hanamaki General Hospital, Japan)
Schedule
Like
)